Introduction
Genome integrity is maintained by DNA damage checkpoints or biochemical pathways that delay or arrest cell cycle progression in response to DNA damage (Nyberg et al., 2002; Sancar et al., 2004) . These regulatory mechanisms inhibit cell cycle progression until the cell has adequately repaired the DNA damage, thus preventing the replication and propagation of potentially deleterious mutations. Importantly, most chemotherapeutic agents elicit checkpoint responses in malignant as well as in normal cells. Therefore, understanding the precise mechanisms of cell cycle checkpoints as well as the factors modulating these mechanisms is critical to develop efficacious cancer treatments.
DNA damage checkpoints mainly cause G1/S arrest to prevent replication of damaged DNA or G2/M arrest to prevent segregation of damaged chromosomes during mitosis (Nyberg et al., 2002; Sancar et al., 2004) . DNA damage-induced activation of p53 plays a critical role in G1/S checkpoint by inactivating the Cdk2 kinase through induction of the cdk inhibitor p21 expression. On the other hand, the G2/M arrest is largely dependent on Chk1-mediated signaling pathway leading to inhibition of the Cyclin B1/Cdc2 activity. Chk1, a serine/ threonine kinase, is activated by phosphorylation on Ser345 by the DNA damage-activated ATM and ATR kinases (Nyberg et al., 2002; Bartek and Lukas, 2003; Sancar et al., 2004) . Activated Chk1 inhibits the Cdc25C phosphatase by phosphorylating Ser216 to promote its association with 14-3-3 proteins. As Cdc25C plays a critical role in dephosphorylation of inhibitory phosphorylation of Cdc2 on Tyr15 and Thr14, the blockage of its activity inhibits activation of Cyclin B1/Cdc2 activity required for the G2/M transition. The Chk2 kinase is also activated by the DNA damage-activated ATM and ATR kinases, but it probably plays more important roles in DNA damage-induced apoptosis than in cell cycle arrest. As the G1/S checkpoint is frequently lost in cancer cells due to mutation of p53, the G2/M checkpoint may have more significant effects on responses of these cells to chemotherapeutic agents (Nyberg et al., 2002; Bartek and Lukas, 2003; Sancar et al., 2004; Zhou and Bartek, 2004) .
The proliferation and apoptosis of hematopoietic progenitor cells are regulated by hematopoietic cytokines, including erythropoietin (Epo) and IL-3. The receptors for Epo and IL-3 mainly couple with a member of the JAK family of tyrosine kinases, Jak2, to activate a similar set of signal transduction pathways, including those involving STAT5, Ras, and phosphatidylinositol 3'-kinase (PI3K) (Ihle, 1995) . A serine/ threonine kinase, Akt, is activated downstream of PI3K to regulate various cellular processes such as apoptosis, cell cycle progression, transcriptional regulation, and glucose uptake by phosphorylating various signaling molecules, including Bad, p21, p27, the forkhead family transcription factors, and glycogen synthase kinase-3 (GSK3) (Brazil et al., 2004) . GSK3, a serine/ threonine kinase, is normally active in cells and is primarily regulated through inhibitory phosphorylation by Akt and other serine/threonine kinases (EldarFinkelman, 2002; Jope and Johnson, 2004) . Recent studies have revealed that GSK3 is a key regulator of numerous signaling pathways and is involved in a wide range of cellular processes, ranging from glycogen metabolism to cell cycle regulation and proliferation. For instance, Epo has been shown to inactivate GSK3 through the PI3K pathway to inhibit apoptosis of erythroid progenitor cells (Somervaille et al., 2001) .
Hematopoietic cytokines such as granulocyte colonystimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and Epo have been widely used after cancer chemotherapy to promote the recovery of hematopoiesis. Moreover, G-CSF has recently been shown to improve the efficacy of chemotherapy on acute myeloid leukemia, most likely by priming leukemic cells into cell cycle progression (Lowenberg et al., 2003) . However, although hematopoietic cytokines play crucial roles in proliferation and survival of normal hematopoietic cells and have some effects on leukemic cells, their effects on cellular responses to DNA-damaging chemotherapeutic agents as well as the molecular mechanisms involved have not been well understood. We demonstrate here that hematopoietic cytokines, Epo and IL-3, play a crucial role in activation of Chk1-dependent checkpoint signaling in response to a DNA-damaging topoisomerase II inhibitor, etoposide, in a hematopoietic model cell line, 32D/EpoR-Wt, as well as in a human leukemic cell line, UT-7. Further examinations reveal that the PI3K/Akt/ GSK3 signaling pathway mediates the enhancement of Chk1-dependent G2/M checkpoint activation leading to inhibition of apoptosis. As the PI3K/Akt pathway is frequently activated in leukemic cells without cytokine stimulation, these findings would contribute significantly to future studies aiming to develop not only cytokine-combined chemotherapies but also novel molecular-targeted therapies against leukemia.
Results

Hematopoietic cytokines promote etoposide-induced G2/ M arrest and prevent apoptosis of hematopoietic cells
To explore the roles of hematopoietic cytokines in modulation of effects of DNA-damaging chemotherapeutic agents on hematopoietic cells, we examined effects of the topoisomerase II inhibitor etoposide on cell cycle progression and viability of a cytokinedependent hematopoietic cell line, 32D/EpoR-Wt, a model hematopoietic progenitor cell line widely used for the studies of cytokine signaling and responses to DNA damages (Miura et al., 1993 (Miura et al., , 1994 Ihle, 1995; Quelle et al., 1998; Eapen et al., 2001; Henry et al., 2001; Arai et al., 2002; Nimbalkar et al., 2003) . As shown in Figure 1a , cells were synchronized in the G0/G1 phase by starvation from cytokine and subsequently stimulated with Epo for 12 h. Cells were then treated with etoposide in the presence or absence of Epo. With or without Epo, cells started to progress into the S and G2/ M phases at around 16 and 20 h, respectively, after the initial Epo stimulation and completed the cell cycle at 24 h in the absence of etoposide (Figure 1b) . In the presence of etoposide and Epo, cells started to accumulate in the G2/M phase at 20 h and remained arrested in this phase at 24 h (Figure 1b) . Very similar results were obtained when cells were cultured with IL-3 instead of Epo (data not shown). On the other hand, etoposide failed to arrest cells in the G2/M phase in the absence of Epo or IL-3 with the subsequent increase in cells in the G1 phase as well as with sub-G1 DNA content, known to be apoptotic cells (Figure 1b) .
We next examined the effects of cytokine on response to etoposide in a human leukemic cell line, UT-7 (Komatsu et al., 1991) , which lacks the normal p53 transcript (Sugimoto et al., 1992) and shows responses to various hematopoietic cytokines, including Epo. As shown in Figure 1c , cells were treated with etoposide for 16 h in the presence or absence of Epo, and the cell cycle distribution was examined. In the absence of Epo, UT-7 cells were arrested in the G0/G1 phase with less than 10% of cells undergoing apoptosis and showing sub-G1 DNA content. In the presence of Epo, etoposide arrested cells in the G2/M phase without causing any significant apoptosis. In contrast, etoposide failed to arrest cells in the G2/M phase and prominently induced apoptosis in the absence of Epo. Together, these results suggest that hematopoietic cytokines Epo and IL-3 promote G2/M checkpoint signaling in response to etoposide and, thus, prevent apoptosis of hematopoietic cells, including leukemic cells with p53 mutation.
Etoposide-induced G2/M arrest is associated with tyrosine phosphorylation of Cdc2 and inhibition of its kinase activity It is well established that onset of mitosis is triggered by activation of the Cyclin B/Cdc2 kinase, which is absolutely required for the transition of G2 cells into M phase (Nyberg et al., 2002; Sancar et al., 2004) . During the G2 phase, Cyclin B/Cdc2 is inactivated by phosphorylation at Thr14 and Tyr15 residues, which is dephosphorylated by Cdc25 phosphatases before going into mitosis. To explore the molecular mechanisms for etoposide-induced G2/M cell cycle arrest in the presence of cytokine, we first examined the Cdc2 kinase activity by the in vitro kinase assay of anti-Cyclin B1 immunoprecipitates using Histone H1 as substrate. As shown in Figure 2a , 32D/EpoR-Wt cells were arrested in G2/M phase by etoposide or in M phase by a mitotic spindle formation inhibitor, nocodazole. Figure 2b demonstrates that the kinase activity of Cyclin B1/Cdc2 from etoposidetreated cells was much lower than that in nocodazoletreated cells. Anti-Cdc2 and anti-phospho-Tyr15-Cdc2 blotting revealed that the anti-Cyclin B1 immunoprecipitate from etoposide-treated cells contained a much higher level of Cdc2, which was heavily phosphorylated on Tyr15, as compared with those from control cells or nocodazole-treated cells. Anti-Cyclin B1 blotting further revealed an increased expression of Cyclin B1 in etoposide-treated cells, which indicates that these cells were arrested in the G2 phase of cell cycle, because Cyclin B1 is rapidly degraded during the M phase. To confirm that etoposide arrests cells prior to mitosis, we also examined mitotic indices of cells treated with etoposide alone or in combination with nocodazole. As shown in Figure 2c , the percentage of cells arrested in mitosis by etoposide treatment was less than 1% with or without co-treatment with nocodazole, while nocodazole alone arrested about 40% cells in mitosis. Together, these results indicate that, in the presence of cytokine, etoposide arrests hematopoietic cells in the G2 phase, most likely due to the inhibition of Cdc2 kinase activity through the persistent inhibitory tyrosine phosphorylation.
Hematopoietic cytokines enhance Chk1-dependent G2/M arrest induced by etoposide treatment As Chk1 has been shown to play a major role in G2/M checkpoint signaling in response to DNA damage (Nyberg et al., 2002; Bartek and Lukas, 2003; Sancar et al., 2004) , we next examined the possible involvement of Chk1 in etoposide-induced G2/M arrest of hematopoietic cells in the presence of cytokine. As shown in Figure 3a , treatment of UT-7 cells with etoposide in the presence of Epo induced a remarkable activationspecific phosphorylation of Chk1 on Ser345, which was observed as early as 1 h after treatment and was sustained as long as 6 h. In contrast, etoposide induced a transient and less significant phosphorylation of Chk1 in the absence of Epo, although reprobing with anti-Chk1, which preferably reacts with the nonphosphorylated form, showed that Chk1 was expressed at comparable levels. Etoposide also induced phosphorylation of p38, which has also been implicated in G2/M checkpoint signaling (Bulavin et al., 2002) . However, Epo failed to show any significant and reproducible effect on etoposide-induced p38 activation ( Figure 3a and data not shown). Using a phosphospecific Chk2 (Thr68) antibody, we failed to observe any inducible phosphorylation of Chk2 in etoposide-treated cells with or without Epo (negative data not shown). Expression levels of Cdc25A and Cdc25C also did not change significantly in response to etoposide with or without Epo (negative data not shown). Consistent with these results with UT-7, Epo as well as IL-3 enhanced etoposide-induced phosphorylation of Chk1, but not that of p38, in 32D/ EpoR-Wt cells (Figure 3b ). These results suggest that the hematopoietic cytokines may promote etoposideinduced cell cycle arrest through enhancement of Chk1 activation.
To explore the role Chk1 plays in induction of G2/M arrest by etoposide, we established a clone of 32Dcl3 (Figure 4a) . Furthermore, the etoposide-induced increase in Cdc2 phosphorylated on Tyr15 was augmented in Chk1-overexpressing cells and was detectable when cells were treated with etoposide at as low as 0.2 mM (Figure 4b ). These results indicate that, as compared with the parental cells, the Chk1-overexpresing cells possess an increased sensitivity to elicit G2/M checkpoint signaling, most likely through induction of the inhibitory phosphorylation of Cdc2, in the presence of IL-3.
We then examined the effect of a Chk1-specific inhibitor, SB218078, on etoposide-induced G2/M arrest. As shown in Figure 4c , SB218078 prevented etoposidetreated cells to arrest at G2/M even in the presence of IL-3 and caused a massive apoptosis, while it did not exhibit any significant effect on cell cycle progression or viability of cells in the absence of etoposide (data not shown). Simultaneous examination by flow cytometry of Cdc2 and cellular DNA content further showed that SB218078 significantly inhibited the etoposide-induced accumulation of Cdc2 phosphorylated on Tyr15 in cells in the G2/M fraction (Figure 4c ). Together, these data indicate that Chk1 plays an important role in G2/M checkpoint activated by etoposide in the presence of cytokine through the persistent inhibitory phosphorylation of Cdc2.
The Akt/GSK3 pathway mediates cytokine enhancement of Chk1-dependent G2/M checkpoint signaling induced by etoposide
We next explored the cytokine signaling pathways that are possibly involved in enhancement of Chk1-dependent G2/M checkpoint in response to etoposide. We first examined the possible involvement of the Ras/Raf/ MEK/Erk signaling pathway, one of the most important signal transduction pathways activated downstream of cytokine receptors, by using the MEK inhibitor PD98059. However, PD98059 did not show any effect on enhancement of etoposide-induced Chk1 phosphorylation by cytokines (data not shown). We next tried to evaluate the possible involvement of the PI3K pathway, which plays a crucial role in inhibition of apoptosis. However, because inhibitors of PI3K may also inhibit the Chk1-activating ATR and ATM kinases, we examined the role of Akt, a downstream effector molecule of PI3K, by using a previously characterized 32D/EpoR-Wt clone that constitutively expresses an activated mutant, Akt-myr, and a clone that inducibly expresses a dominant negative Akt mutant, Akt-KM (Arai et al., 2002) . As shown in Figure 5a , etoposide (Figure 2c ), the mitotic index for the Akt-myr-expressing cells arrested by etoposide in the absence of cytokine was less than 1%, thus indicating that cells were arrested in the G2 phase (data not shown). Furthermore, apoptosis induced by etoposide in the absence of Epo was significantly reduced in Aktmyr-expressing cells as compared with parental cells (Figure 5a ). In contrast, when the expression of Akt-KM was induced by withdrawal from tetracycline, 32DE/Tet-Akt-KM cells cultured in Epo exhibited a Figure 4 Chk1 plays a role in etoposide-induced G2/M checkpoint signaling through the inhibitory Cdc2 phosphorylation to prevent apoptosis of hematopoietic cells. (a) 32Dcl3 or a 32Dcl3 clone overexpressing Chk1 (32D/Chk1) was treated with or without 0.2 mM etoposide, as indicated, for 16 h in the presence of IL-3. Cells were stained with propidium iodide, and DNA content of cells was analysed by flow cytometry. (b) 32Dcl3 or 32D/Chk1 was treated with etoposide at indicated concentrations for 16 h in the presence of IL-3. Cells were lysed and subjected to Western blot analysis with anti-phospho-Tyr15-Cdc2 antibody, followed by reprobing with anti-Cdc2 and anti-Chk1 antibodies, as indicated. Transfected Chk1 tagged with HA and endogenous Chk1 are indicated by long and short arrows, respectively. (c) 32Dcl3 cells in IL-3-containing medium were pretreated with or without 1 mM of the Chk1 inhibitor SB218078, as indicated, and then treated with 1 mM etoposide for 16 h or left untreated as control. Flow cytometric analyses for cellular DNA content by propidium iodide staining (upper panels), for Cdc2 phosphorylation on Tyr15 simultaneously with DNA content by anti-phospho-Cdc2-Y15 and propidium iodide staining (middle panels), and for apoptosis by Annexin V and propidium iodide staining (lower panels) were then performed Figure 5 Akt plays a role in Epo-dependent G2/M checkpoint activation in response to etoposide. (a) 32D/EpoR-Wt or a clone expressing the activated Akt mutant (32DE/Akt-myr) was treated with or without 1 mM etoposide, as indicated, for 16 h in the absence of Epo and IL-3. Flow cytometric analyses for DNA content of cells by propidium iodide staining (left and center panels) and for apoptosis by Annexin V and propidium iodide staining (right panels) were then performed. (b) 32DE/Tet-Akt-KM cells were washed out from tetracycline to induce expression of the dominantnegative Akt mutant (TetÀ) or cultured in tetracycline-containing medium as control (Tet þ ). Cells were then treated with or without 1 mM etoposide, as indicated, for 16 h in the presence of Epo but without IL-3 and analysed by flow cytometry as described above decrease in G2/M arrest and an increase in apoptosis in response to etoposide as compared with cells not withdrawn from tetracycline (Figure 5b ). These results suggest that Akt, activated downstream of cytokine receptors, plays a role in enhancement of etoposideinduced G2/M checkpoint signaling and in inhibition of apoptosis.
To determine the downstream signaling molecule of PI3K/Akt signaling pathway involved in enhancement of etoposide-induced G2/M checkpoint in hematopoietic cells, we next examined the possible role of GSK3, which is regulated by inhibitory phosphorylation by Akt (Eldar-Finkelman, 2002; Jope and Johnson, 2004) . Figure 6a shows that, when cells were pretreated with a GSK3 inhibitors, SB216763 or LiCl, etoposide significantly induced G2/M arrest of UT-7 cells even in the absence of Epo. SB216763 or LiCl also significantly reduced apoptosis induced by etoposide in the absence of Epo. Furthermore, both SB216763 and LiCl significantly enhanced etoposide-induced Chk1 phosphorylation in the absence as well as in presence of Epo (Figure 6b ). Together, these results strongly implicate inactivation of GSK3 by the PI3K/Akt pathway in enhancement of Chk1-dependent G2/M checkpoint signaling in response to etoposide.
Discussion
The present study demonstrates that hematopoietic cells treated with etoposide arrest in G2/M or, alternatively, undergo apoptosis in the presence or absence of hematopoietic cytokines, respectively (Figure 1 ). In cells arrested in G2/M, the expression level of Cyclin B1/ Cdc2 complex was high, but the kinase activity of Cyclin B1-associated Cdc2 was very low, most likely through the inhibitory phosphorylation on Thr14 and Tyr15 (Figure 2 ). The present study further revealed that Epo or IL-3 significantly enhances activation-specific phosphorylation of Chk1 on S345 induced by treatment with etoposide, which correlated with the G2/M arrest (Figure 3) . Moreover, the G2/M arrest induced by etoposide treatment in the presence of cytokine was augmented or inhibited by overexpression of Chk1 or by treatment with the Chk1 specific inhibitor, respectively, which suggests that Chk1 plays a role in G2/M checkpoint activation by etoposide in the presence of cytokine (Figure 4 ). 32D cells expressing the constitutively activated Akt arrested in G2/M in response to etoposide even in the absence of cytokines and underwent significantly less apoptosis than parental 32D cells. In contrast, the induced expression of dominantnegative Akt significantly inhibited the etoposideinduced G2/M arrest in the presence of Epo and aggravated apoptosis ( Figure 5) . Moreover, the pharmacological inhibition of GSK3, a downstream target molecule of Akt, significantly enhanced the etoposideinduced activation of Chk1 as well as G2/M arrest and inhibited apoptosis (Figure 6 ). Together, these results indicate that IL-3 or Epo augments Chk1-dependent G2/M checkpoint activation in response to etoposide through the Akt/GSK3 pathway and, thereby, prevents apoptosis of hematopoietic cells, including leukemic cells with mutated p53.
It has been well established that hematopoietic cytokines protect hematopoietic cells from apoptosis induced by various DNA-damaging agents (Collins et al., 1992; Canman et al., 1995) . Canman et al. (1995) further showed that IL-3 plays a role in G1 checkpoint activation in response to g-irradiation in BaF3 cells through enhancement of p21 expression. Concordant with this, the present study has demonstrated that Epo as well as IL-3 promotes Chk1-dependent G2/M checkpoint activation in response to etoposide through PI3K/Akt/GSK3 signaling pathway. In contrast, Quelle and his co-workers showed that Epo or IL-3 overrides g-irradiation-induced G1 arrest of 32D cells by activating Cdk2 in a PI3K-dependent manner (Quelle et al., 1998; Eapen et al., 2001; Henry et al., 2001) . Furthermore, these researchers recently reported that cytokine activation of PI3K signaling pathways overrides cisplatin-induced growth arrest, thereby sensitizing hematopoietic cells to DNA damage-induced death (Nimbalkar et al., 2003) . The apparent discrepancy may be caused by the differences in experimental conditions such as the observation periods and DNAdamaging agents utilized, and most likely reflects dual roles cytokines may play in hematopoietic cells undergoing DNA damages. First, the effect of cytokine on Chk1-mediated G2/M checkpoint signaling was observed as early as 1 h after treatment with etoposide (Figure 3a) , whereas a significant time lag of 16 h was required before cytokines induced PI3K-dependent Cdk2 activation to override G1 arrest of g-irradiated cells . Second, in the report by Nimbalkar et al. (2003) , 32D/EpoR-Wt cells were in fact arrested in G2/M in the presence of Epo at 24 h after cisplatin treatment and only later showed greater UT-7 cells were resuspended in medium with or without Epo and pretreated with or without 20 mM LiCl or 5 mM SB216763 for 45 min, as indicated. Cells were then treated with or without 1 mM etoposide for 6 h, as indicated, and subjected to Western blot analysis with anti-phospho-Chk1 antibody, followed by reprobing with anti-Chk1, as indicated increases in cell death as compared with cells stably arrested by inhibition of PI3K. Thus, hematopoietic cytokines may play a role in G1 checkpoint activation through inducing a sustained induction of p21, as suggested by Canman et al. (1995) , or in G2/M checkpoint activation through enhancing Chk1 activation and, yet, later override the cell cycle arrest through PI3K-dependent mechanisms, which are known to play important roles in cell cycle progression (Brazil et al., 2004) . The discrepant effects of cytokines on cell viability may then be explained by the different conditions of DNA damage, because the forced recovery from cell cycle arrest before the DNA damage repair should result in massive cell death (Nyberg et al., 2002; Sancar et al., 2004) .
Intriguingly, Shtivelman et al. (2002) recently reported that inhibition of PI3K resulted in activation of Chk1 in epithelial cells, in which Akt activity is increased in the G2/M phase. Furthermore, expression of constitutively activated Akt phosphorylated Chk1 on Ser280 and inhibited the ability of Chk1 to undergo activating phosphorylation on Ser345 after replication arrest induced by hydroxyurea (King et al., 2004) . Thus, PI3K/Akt signaling may play different roles in checkpoint activation in response to replication arrest induced by hydroxyurea and to DNA damage induced by etoposide. Alternatively, the apparent contradiction between these reports and our results may be due to the differences in cell types examined. In the report by Shtivelman et al. (2002) , inhibition of PI3K in epithelial cells induced the G2/M arrest and apoptosis. However, in fibroblasts, in which Akt activity is not increased in the G2/M phase, inhibition of PI3K predominantly induced the G1 arrest, thus implying that PI3K/Akt signaling (Shtivelman et al., 2002) may play different roles in these different types of adherent cells. Thus, it is plausible that PI3K/Akt signaling may play a quite different role in checkpoint activation in hematopoietic cells as compared with epithelial cells.
GSK3 has been implicated in the regulation of a wide range of cellular processes including, apoptosis, proliferation, differentiation, and metabolism (Eldar-Finkelman, 2002; Jope and Johnson, 2004) . Previously, Somervaille et al. (2001) have shown that the Epodependent inhibition of GSK3 through the PI3K/Akt pathway is essential for prevention of apoptosis of erythroid progenitor cells. The present study further demonstrated that the cytokine-dependent inhibition of GSK3 plays a role in prevention of DNA damageinduced apoptosis of hematopoietic cells through enhancement of Chk1-dependent checkpoint activation. Intriguingly, apoptotic stimuli, including DNA damage induced by etoposide, have been shown to induce translocation of GSK3 to the nucleus, where it directly interacts with and is activated by p53 to enhance the apoptotic effects of p53 (Bijur and Jope, 2001; Watcharasit et al., 2002 Watcharasit et al., , 2003 . Taken together, these observations indicate that GSK3 should play critical roles in regulation of cellular responses to DNA damage. In this regard, it is noteworthy that lithium treatment reduced chemotherapy-induced neutropenia and febrile complications of marrow suppressive therapies in a number of clinical trials, although the plasma therapeutic range is below the 50% inhibitory concentration for GSK3 (Phiel and Klein, 2001) . Although the enhancement of Chk1 activation was observed as early as 6 h after the inhibition of GSK3 (Figure 6 ), it is unlikely that GSK3 directly interacts with and phosphorylates Chk1, because we could not observe the complex formation of GSK3 and Chk1 (data not shown), which lacks the consensus sequence for GSK3 substrate, S/T-X-X-X-S/T-P. Thus, the molecular mechanisms involved in GSK3-mediated inhibition of Chk1 activation in response to DNA damage remain to be elucidated in future studies.
Recent studies have established that, in contrast to normal CD34-positive hematopoietic progenitor cells, the PI3K/Akt signaling pathway is constitutively activated in the majority of primary acute myeloid leukemia samples, which correlated with a poor prognosis Xu et al., 2003; Kubota et al., 2004; Zhao et al., 2004) . This may be caused by mutations of PI3K activators, such as Ras, FLT3, and c-Kit, or by downmodulation of the phosphatases PTEN and SHIP that act as negative regulators of PI3K (Xu et al., 2003; Steelman et al., 2004) . Furthermore, according to a recent study , GSK3 is phosphorylated in association with constitutively activated Akt in a majority of cases with acute myeloid leukemia, which also correlated with a poor prognosis. It is hypothesized that the Chk1-dependent checkpoint activation in response to chemotherapy may be constitutively enhanced in these cases, which may partly explain the poor prognosis. Then, pharmacological intervention of the PI3K/Akt/GSK3 pathway (Eldar-Finkelman, 2002; Brazil et al., 2004) should increase the chemosensitivity of these leukemias, especially those with defective G1 checkpoint with mutation of p53. Alternatively, administration of cytokine along with chemotherapy in these cases may enhance the Chk1-dependent checkpoint selectively in normal hematopoietic progenitor cells, thus widening the therapeutic window. Future studies are needed to address these hypothetical possibilities to develop efficient new therapeutic strategies for leukemia.
Materials and methods
Cells and reagents
A murine IL-3-dependent cell line, 32Dcl3, and a clone of 32Dcl3 expressing the Epo receptor, 32D/EpoR-Wt, have been previously described (Miura et al., 1993) and maintained in RPMI1640 medium supplemented with 10% FCS and 10% WEHI conditioned medium as the source of IL-3 or 1 U/ml human recombinant Epo. A clone of 32D/EpoR-Wt that constitutively expresses the activated Akt mutant myr-Akt, 32DE/Akt-myr, or a clone that inducibly expresses the dominant-negative Akt mutant Akt-K179M, 32DE/Tet-Akt-KM, has also been described previously (Arai et al., 2002) . A human leukemic cell line expressing the endogenous Epo receptor, UT-7 (Komatsu et al., 1991) , was kindly provided by Dr Norio Komatsu (Jichi Medical School, Tochigi, Japan).
Recombinant human Epo was kindly provided by Chugai Pharmaceutical Co. Ltd. (Tokyo, Japan) and was used at 1 U/ ml. Recombinant murine IL-3 was purchased from PeproTech Inc. (Rocky Hill, NJ, USA) and was used at 10 U/ml. Etoposide was purchased from Wako (Tokyo Japan). The MEK1 inhibitor PD98059, the Chk1 inhibitor SB218078 (Jackson et al., 2000) , the GSK3 inhibitor SB216763 (Coghlan et al., 2000) , and nocodazole were purchased from Calbiochem (La Jolla, CA, USA). Blasticidin-S was purchased from Funakoshi (Tokyo, Japan).
Rabbit polyclonal antibodies against phospho-Chk1 (Ser345), phospho-Chk2 (Thr68), phospho-Cdc2 (Tyr15), phospho-p38 (Thr180/Tyr182), and p38 were purchased from Cell Signaling Technology (Beverly, MA, USA). Rabbit polyclonal antibodies against Cdc25A (144), Cdc25C (C-20), and Chk1 (FL-476) as well as mouse monoclonal antibodies against Cdc2 (17) and Cyclin B1 (GNS1) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Other reagents were purchased from Sigma (St Louis, MO, USA) unless described otherwise.
Flow cytometric analyses of apoptosis and cell cycle
For flow cytometric analysis of apoptosis, phosphatidylserine exposure on the outer leaflet of the plasma membrane was detected using the TACS Annexin V Kit (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions. In brief, 1 Â 10 6 cells were resuspended in 100 ml of binding buffer containing of annexin V-FITC and propidium iodide (PI) and incubated for 15 min. After 400 ml of binding buffer was added, the cells were analysed using a Becton Dickinson FACSscan flow cytometer (Mountain View, CA, USA).
For cell cycle analysis, cells were resuspended in Krishan's reagent (0.05 mg/ml PI, 0.1% Na citrate, 0.02 mg/ml ribonuclease A, 0.3% NP-40) at a concentration of 1 Â 10 6 cells/ml. After incubation for 30 min on ice, cells were analysed by flow cytometry. For multivariate flow cytometric cell cycle analysis, cells were simultaneously stained for DNA content with PI and for Cdc2 phosphorylated on Tyr15 with primary and FITCconjugated secondary antibodies as previously described (Sramkoski et al., 1999) . FITC-conjugated goat F(ab 0 )2 fragment anti-rabbit IgG (H þ L) antibody was purchased from Beckman Coulter (Miami, FL, USA).
Mitotic index assays
Cells were cultured for 16 h with or without indicated concentrations of etoposide and 500 ng/ml nocodazole. Cytospin preparation prepared was fixed and stained with Wright's stain solution. Mitotic cells were scored by randomly counting 200 cells by light microscopy to calculate the mitotic index (%).
Cell transfection
An expression plasmid for HA-tagged Chk1, PEF-BOS-HAChk1 (Sarkaria et al., 1999) , was kindly provided by Dr Jann N Sarkaria. Transfection for stable expression was carried out essentially as described previously (Miura et al., 1993) . In brief, 32Dcl3 cells were transfected with 10 mg of PEF-BOS-HAChk1Wt and 1 mg of PMAM2-BSD, purchased from Funakoshi (Tokyo, Japan), by electroporation at 280 V and 960 mF using Gene Pulser apparatus (BioRad, Hercules, CA, USA). Transfected cells were selected in medium containing blasticidin-S. Six clones were isolated by limiting dilution for transfection and the clone expressing highest level of HAtagged Chk1 were used for subsequent experiments.
Immunoprecipitation, immunoblotting, and Cdc2 kinase assay
For immunoprecipitation experiments, cells were lysed in a lysis buffer containing 1% Triton X-100, 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 mM bglycerophosphate, 1 mM sodium orthovanadate, and 10 mg/ml each of aprotinin and leupeptin. Cell lysates were subjected to immunoprecipitation and immunoblotting as described previously (Miura et al., 1994) . For immunoblot analysis of total cell lysates, samples were prepared by mixing an aliquot of cell lysates with an equal volume of 2 Â Laemmli's sample buffer and heating at 1001C for 5 min.
To assay the Cdc2 kinase activity, cell lysates were immunoprecipitated with anti-Cyclin B1 antibody. The immunoprecipitates were subjected to the in vitro kinase assay using the Cdk1/Cdc2 kinase assay kit (Upstate Biotechnology, Lake Placid, NY, USA) according to the manufacturer's protocol.
